Waking up with blurred vision and pain when you move your eye is frightening. Optic neuritis is serious. But it is treatable, and most people recover most of their vision. What matters is acting quickly and understanding what comes next.

Optic neuritis is an inflammation of the optic nerve, the cable that carries visual signals from the eye to the brain. It typically causes sudden vision loss in one eye, often accompanied by pain that worsens with eye movement, and reduced colour perception. It most commonly affects young adults between 20 and 40, with a strong predisposition for women. Optic neuritis matters not only because of the vision loss it causes, which usually recovers well, but because it is frequently the first presenting symptom of multiple sclerosis. Understanding what it means for long-term neurological health is as important as treating the acute episode.

What You Need to Know About Optic Neuritis

Optic neuritis causes sudden vision loss in one eye, pain on eye movement, and washed-out colour perception, developing over hours to days
Most patients recover most of their vision within weeks to months, often without treatment
Intravenous steroids speed recovery but do not improve the final visual outcome
Around 50 percent of people presenting with a first episode of optic neuritis will develop multiple sclerosis within 15 years
MRI of the brain at the time of optic neuritis is the most important predictor of MS risk and guides decisions about disease-modifying treatment
Recurrent optic neuritis or optic neuritis that doesn’t recover well should raise suspicion for NMOSD and MOG antibody disease

Visual recovery ~90% Of patients recover vision to 20/40 or better within 6 months

MS risk at 15 years ~50% Of optic neuritis patients develop MS over 15 years

Most affected Women 20-40 Years old, though it can occur at any age

Symptoms

Vision loss

The vision loss of optic neuritis develops over hours to a few days and ranges from mild blurring to severe reduction. It is almost always monocular, affecting one eye, in typical demyelinating optic neuritis. Central vision is most prominently affected, often producing a dark or blurred patch at the center of the visual field. Side vision is usually better preserved.

Side-by-side comparison of vision in optic neuritis: left image shows the affected eye's view with a dark central scotoma and washed-out colors; right image shows the same scene through the normal eye with full clarity — Left: vision through an eye with acute optic neuritis, with central blurring and reduced colour. Right: the same scene through the unaffected eye.

Pain

Pain with eye movement is present in around 90 percent of patients and is often the first symptom, sometimes preceding the vision loss by a day or two. It’s typically described as an aching or pressure sensation behind the eye that worsens when the eyes move, particularly in extreme gaze. The pain usually resolves within a couple of weeks regardless of treatment.

Colour desaturation

Even when visual acuity appears relatively preserved, patients with optic neuritis characteristically notice that colours look washed out or less vivid in the affected eye. Red objects in particular look duller or less saturated than through the normal eye. This red desaturation is a clinically important sign and often persists even after visual acuity has fully recovered, because fine colour transmission requires intact optic nerve function beyond simple acuity.

Uhthoff’s phenomenon

Many patients notice their vision temporarily worsens with exercise, hot showers, or fever. This is Uhthoff’s phenomenon: raised body temperature further impairs conduction in already inflamed nerve fibres. It is benign and reverses once the body cools. Alarming if you don’t know to expect it. It does not indicate that the nerve is being further damaged. Worth knowing before a summer run puts you through it unexpectedly.

Diagnosis

Clinical examination

The diagnosis is primarily clinical. The ophthalmologist assesses visual acuity, colour vision, the visual field, and the relative afferent pupillary defect (RAPD), a difference in the pupil’s response to light between the two eyes that indicates reduced optic nerve function on the affected side. In typical optic neuritis the optic disc looks normal on examination because the inflammation is usually behind the eye. OCT of the retinal nerve fibre layer provides an objective baseline measurement of optic nerve fibre thickness, which will thin during recovery as damaged fibres are lost.

MRI

MRI of the brain and orbits is performed in all patients with optic neuritis. It serves two purposes: confirming the diagnosis by showing signal change along the optic nerve, and assessing the brain for white matter lesions that indicate subclinical demyelination and push the risk of developing MS considerably higher.

Axial brain MRI at orbital level showing both optic nerves, with the left optic nerve shown on the right side of the image displaying a red-orange glow illustrating the site of inflammation in optic neuritis — Axial MRI at orbital level. The red glow on the right side of the image is an illustration added to highlight the affected nerve. On an actual MRI scan, the finding is a subtle signal change along the nerve length, not visible as a glow.

Blood tests

MOG and AQP4 antibodies are measured in all patients, particularly those with atypical features, because MOG antibody disease and NMOSD require different long-term management from MS-associated optic neuritis. Vitamin B12, inflammatory markers, and ACE level are checked where clinically indicated.

Treatment

Intravenous methylprednisolone

The standard treatment for acute optic neuritis is a three to five day course of high-dose intravenous methylprednisolone. This speeds the rate of visual recovery by approximately two to four weeks compared to no treatment, allowing patients to return to normal activities sooner. The landmark Optic Neuritis Treatment Trial established clearly that steroids do not improve the final level of vision achieved. The outcome at six months and beyond is the same whether or not steroids are given. The decision to treat depends on how severely the vision loss is affecting daily life.

Oral prednisolone alone at standard doses is not recommended because the original trial showed an unexpectedly higher rate of recurrence in the oral steroid group. If oral steroids are used, they should follow rather than replace the intravenous course.

Disease-modifying treatment for MS

For patients whose MRI shows white matter lesions indicating high MS risk, early referral to neurology for consideration of disease-modifying therapy is important. The CHAMPS and CHAMPIONS trials showed that starting a disease-modifying drug after a first demyelinating event cuts the risk of a second event substantially and delays the diagnosis of clinically definite MS. The decision is made jointly by the neurologist from the neuro-ophthalmology team and patient based on MRI findings, personal circumstances, and tolerance of risk.

Optic Neuritis and Multiple Sclerosis

Every single patient asks this question. Having a single episode of optic neuritis does not mean you will develop MS, but it does mean your risk is elevated above the general population. How much elevated depends enormously on what the MRI shows.

In the Optic Neuritis Treatment Trial, patients with no white matter lesions on MRI at the time of optic neuritis had only a 25 percent risk of developing MS over 15 years. Patients with two or more white matter lesions had a risk of around 72 percent. The MRI is not just a diagnostic test. It is a prognostic one, and its findings drive all decisions about monitoring and preventive treatment.

MS-associated optic neuritis has a better prognosis for visual recovery than NMOSD or MOG antibody disease. If your antibody tests are negative and your MRI is consistent with demyelination, that is the form of optic neuritis with the best visual outlook. Discussing your specific results with your ophthalmologist and neurologist gives you the clearest picture of your individual situation.

Seek Urgent Assessment the Same Day If You Have

Sudden vision loss in one eye, with or without pain on eye movement
Sudden loss of vision in both eyes simultaneously, which is atypical and needs urgent exclusion of other causes
Vision loss that is rapidly worsening over hours
A known optic neuritis patient whose vision deteriorates again after a period of recovery
Optic neuritis alongside limb weakness, sensory disturbance, or difficulty with balance

Optic neuritis requires same-day assessment to confirm the diagnosis, exclude other causes of sudden vision loss such as retinal detachment or vascular occlusion, and arrange urgent MRI and neurology review. Don’t wait for a routine appointment. Contact your eye unit or go to an emergency eye service the same day.

Frequently Asked Questions About Optic Neuritis

Will my vision fully recover?
In most cases, yes. Around 90 percent of patients with typical demyelinating optic neuritis recover vision to 20/40 or better within six months, and many recover to 20/20. Recovery begins within the first few weeks and continues for up to a year. Patience matters here. Even with good acuity recovery, some residual symptoms often persist, particularly subtle colour desaturation and Uhthoff’s phenomenon with heat or exercise. These reflect incomplete remyelination but they don’t indicate ongoing damage to the nerve.
Do I need steroids?
Steroids speed recovery but don’t change the final outcome. If your vision loss is mild and not badly affecting your daily life, watchful waiting and natural recovery is entirely reasonable. If the vision loss is severe, or if you have work or driving demands that make early recovery important, intravenous steroids are worth discussing. The decision should be made with full information about what steroids can and cannot achieve.
Does optic neuritis mean I have MS?
Not necessarily. A single episode raises your lifetime risk but doesn’t confirm the diagnosis. The key prognostic test is the brain MRI. No white matter lesions means a 15-year MS risk of around 25 percent. Multiple lesions means the risk is much higher. Your neurologist will use the MRI findings, clinical features, and antibody results to give you a clearer personal risk estimate and advise on whether early preventive treatment is appropriate.
Why does my vision get worse when I exercise or have a hot shower?
Uhthoff’s phenomenon. Raising body temperature impairs conduction in nerve fibres that are inflamed or incompletely remyelinated. The effect is temporary and reverses once the body cools. It doesn’t cause any additional damage to the nerve. It can persist for months or years after the acute episode. Worth knowing before the next gym session.
Can optic neuritis happen again?
Yes. Recurrence in the same or fellow eye is possible, particularly in patients who go on to develop MS. Very severe optic neuritis that doesn’t recover well, or recurrence in the same eye, should prompt retesting for MOG antibody disease and NMOSD, as these are prone to recurrence and require different preventive treatment. If you’ve had optic neuritis before and notice new visual symptoms, get assessed promptly. Don’t assume it will follow the same course. It may not.
Is there anything I can do to protect my optic nerve long-term?
For patients at high MS risk based on MRI findings, disease-modifying therapy started early after a first episode reduces relapse rates and slows brain lesion accumulation. Beyond this, general measures that support neurological health apply: regular exercise, not smoking, adequate vitamin D, and a healthy weight all have evidence linking them to better MS outcomes. Discuss what is relevant to your specific risk profile with your neurologist.

If you would like to learn more, the NCBI StatPearls review on optic neuritis offers a detailed medical overview of causes, symptoms, diagnosis, imaging, and treatment, while the North American Neuro-Ophthalmology Society page on optic neuritis provides a patient-friendly explanation of symptoms, MRI evaluation, treatment, prognosis, and the link with multiple sclerosis.

Optic neuritis (ON) is inflammation of the optic nerve producing acute, usually monocular, visual loss , typically over hours to days , accompanied by periocular pain that worsens on eye movement and a relative afferent pupillary defect (RAPD). The most clinically significant aspect of optic neuritis is its relationship to demyelinating disease: in a patient with a first episode of ON and a brain MRI showing two or more T2 white-matter lesions, the 15-year risk of developing clinically definite multiple sclerosis (MS) exceeds 72% (ONTT long-term follow-up data). Management centers on high-dose IV methylprednisolone to accelerate visual recovery (without improving the final visual outcome), and on MS risk counseling and early disease-modifying therapy (DMT) when the risk is high. Visual prognosis after a single episode is generally good: over 90% of patients recover to 6/12 or better within 6-12 months.

Clinical Overview: Optic Neuritis

Classic presentation: Acute monocular visual loss, dyschromatopsia (red desaturation often noticed first), periocular pain on eye movement (92% of cases), RAPD if unilateral, central or cecocentral scotoma on VF, normal optic disc in two thirds of cases (retrobulbar ON) or disc swelling in one third (papillitis, more common in children)
ONTT (Optic Neuritis Treatment Trial): IV methylprednisolone 250 mg QDS × 3 days → oral prednisolone × 11 days accelerates visual recovery by approximately 2 weeks vs placebo; no difference in final VA at 6 months. Oral prednisolone alone (1 mg/kg) in the ONTT increased the relapse rate , do not use oral steroids alone for acute ON. IV steroids are appropriate when vision is severely affected or when the patient needs rapid return to function.
MS risk stratification: MRI brain at presentation is the single most important prognostic test. ONTT: 0 T2 lesions = 25% MS risk at 15 years; 1-2 lesions = 60%; ≥3 lesions = 72%+. High-risk findings: lesions perpendicular to ventricles (Dawson’s fingers), corpus callosum involvement, posterior fossa lesions. Refer to neurology for McDonald criteria assessment.
CSF: Not routinely required for typical ON. Indicated if: MRI findings atypical, bilateral simultaneous ON, very poor recovery, suspected NMO (neuromyelitis optica spectrum disorder). NMO: anti-AQP4 antibody positive; bilateral severe ON, longitudinally extensive transverse myelitis; different treatment and prognosis from MS-related ON.
OCT: RNFL thinning on OCT follows the ON episode by 3-6 months (Wallerian degeneration). OCT-RNFL thickness correlates with final visual function and can detect subclinical fellow eye involvement. Useful for monitoring , a second thinning episode in the same eye suggests recurrent ON.
Disease-modifying therapy (DMT): For high MS risk (≥2 MRI lesions): CHAMPS/CHAMPIONS trial showed that starting interferon-beta-1a immediately after ON reduces 3-year MS conversion by approximately 50% vs placebo. Neurology should discuss DMT early. High-efficacy DMTs (natalizumab, ocrelizumab) preferred for high-risk patients.

Visual recovery (>6/12) >90% Of typical ON cases recover to 6/12 or better within 12 months

15-year MS risk (≥3 lesions) >72% With 3+ MRI T2 lesions at ON presentation (ONTT)

DMT effect on conversion ~50% Reduction in 3-year MS conversion with early IFN-β1a (CHAMPS)

Pathophysiology

In MS-related ON, autoreactive T-cells breach the blood-brain barrier and target myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and aquaporin-4 (AQP4). Demyelination of the optic nerve impairs saltatory conduction along axons, causing visual loss. The periocular pain results from inflammatory involvement of the meningeal sheath around the nerve. Early inflammatory edema (Uhthoff phenomenon: transient worsening in heat or exercise) is characteristic of demyelinating disease and can help distinguish ON from compressive or ischemic optic neuropathy.

NMO spectrum disorder (NMOSD): Anti-AQP4-IgG positive NMOSD causes a more severe ON than MS-related disease , bilateral in 30%, worse nadir VA (often counting fingers or hand movements), and poorer recovery. Seronegative NMOSD may have anti-MOG-IgG positivity. The distinction matters clinically: NMOSD relapses can be catastrophic, and interferon-beta therapy (used in MS) can worsen NMOSD. Test AQP4-IgG in all atypical ON, bilateral simultaneous ON, or cases with poor recovery.

Atypical features that should prompt alternative diagnoses: No pain, no light perception at nadir, severe disc swelling, macular star or exudates, bilateral simultaneous onset (consider NMOSD, Leber hereditary optic neuropathy [LHON], compressive lesion), non-improving or worsening VA beyond 6 weeks, age over 50 (anterior ischemic optic neuropathy [AION] more common), recurrent ON in the same eye with no MS diagnosis.

Side-by-side comparison of vision in optic neuritis: left image shows normal clear vision, right shows blurred central vision with a central scotoma typical of acute optic neuritis — Optic neuritis visual impact: normal vision (left) vs central scotoma and dyschromatopsia (right). Central field loss with periocular movement pain is the classic presentation.

Investigation

MRI brain and orbits: Fundus photography and gadolinium-enhanced MRI of the brain and orbits at presentation. Orbital fat suppression sequences show enhancement of the affected optic nerve (confirms active inflammation). Brain T2/FLAIR sequences identify demyelinating white-matter lesions. Corpus callosum, periventricular, and infratentorial lesions carry the highest MS risk. Spinal cord MRI if myelopathy symptoms are present (NMOSD assessment).

Visual field testing: Humphrey 24-2 documents the field defect pattern (central scotoma, cecocentral scotoma in ON; altitudinal defect in AION; bitemporal in chiasmal compression). Serial fields track recovery and detect recurrence. The ONTT found that initial VF pattern did not predict final VA outcome , recovery is generally good regardless of initial severity.

Blood tests: AQP4-IgG and MOG-IgG (NMOSD screening), VEP (visual evoked potentials , prolonged P100 latency from demyelination; useful in subclinical involvement and in monitoring), ACE and chest X-ray (sarcoid ON), syphilis serology, Lyme antibodies if endemic area exposure, vitamin B12 (nutritional optic neuropathy differential).

Management

IV methylprednisolone: 1 g IV daily for 3 days (or 250 mg QDS × 3 days). Accelerates visual recovery by approximately 2 weeks without improving final VA at 6 months. Indicated when: VA is severely reduced (6/36 or worse), the patient has a high-demand job requiring rapid return to function, or the fellow eye is also affected. Not universally recommended for mild to moderate ON , the decision is shared with the patient based on how much the delay in recovery affects their function.

Neurology referral and DMT: Any patient with ON and MRI white-matter lesions should be referred to neurology for McDonald criteria assessment and DMT discussion. The CHAMPS trial (interferon-beta-1a 30 µg IM weekly) showed 44% relative risk reduction in 3-year MS diagnosis in high-risk patients. Current practice favors high-efficacy DMTs (ocrelizumab, natalizumab) over platform therapies (interferon, glatiramer) for high-risk cases. NMOSD requires different treatment (rituximab, eculizumab, inebilizumab) , never interferon-beta.

Axial brain MRI at orbital level showing both optic nerves, with the left optic nerve showing gadolinium enhancement indicating active demyelination in optic neuritis — MRI orbit: gadolinium enhancement of the left optic nerve confirming active demyelinating ON. T2 white-matter lesions on brain sequences determine MS risk stratification.

Clinical Decision Points

Typical ON, VA 6/18, MRI brain clear: Counsel regarding low MS risk (25% at 15 years). IV steroids optional , discuss with patient. Neurology referral to confirm CIS (clinically isolated syndrome) status and discuss monitoring. No DMT indicated for clear brain MRI.
ON, VA counting fingers, 3 MRI lesions: IV methylprednisolone immediately. Urgent neurology referral , McDonald criteria may already be met (MRI lesion dissemination in space + ON). Early high-efficacy DMT discussion.
Bilateral simultaneous ON: Not typical MS. Test AQP4-IgG and MOG-IgG. Exclude LHON (mitochondrial genetics in young males). Consider MRI spine. Do not start interferon-beta until NMOSD excluded.
Poor recovery at 6 weeks: Reassess diagnosis. MRI orbit with gadolinium. Exclude compressive lesion. Test AQP4-IgG, MOG-IgG. VEP. Consider repeat VF , “poor recovery” by subjective report sometimes masks objective improvement.
Known MS patient with new monocular VA reduction: Optic neuritis relapse. IV methylprednisolone as above. Review DMT efficacy with neurologist , breakthrough ON on DMT is an indication to escalate therapy.

Same-Day Assessment Required

Bilateral simultaneous vision loss with disc swelling , may represent bilateral AION, severe papilledema from raised ICP, or bilateral NMOSD; emergency assessment
Visual loss plus severe headache, meningism, or focal neurology , exclude intracranial mass, meningitis; emergency neuroimaging
Monocular visual loss, age over 50, no pain, altitudinal field loss , anterior ischemic optic neuropathy (AION), not ON; check ESR and CRP immediately to exclude giant cell arteritis (GCA)

Giant cell arteritis presenting as anterior ischemic optic neuropathy (AION-GCA) can be indistinguishable from ON in the first hours. Temporal artery biopsy and ESR are the investigations, not MRI. Missing GCA means the fellow eye may lose vision within days. Any visual loss in a patient over 50 with headache, jaw claudication, or scalp tenderness requires immediate ESR/CRP and high-dose systemic steroids while awaiting biopsy , not MRI brain first.

Clinical Pearls: Optic Neuritis

Oral prednisolone alone increases the ON relapse rate. Never use it as monotherapy for acute ON.
This is one of the few counterintuitive findings in ophthalmology with strong trial evidence. The ONTT found that patients randomized to oral prednisolone 1 mg/kg/day for 14 days had a significantly higher ON relapse rate at 6 months compared with IV methylprednisolone or placebo. The mechanism is unclear but may relate to incomplete immunosuppression with low-dose oral steroids stimulating partial immune responses. The implication: if you decide to treat ON with steroids, use IV methylprednisolone. If you do not use IV steroids, give nothing , not a tapering course of oral prednisolone.
A normal disc in acute visual loss does not exclude optic nerve disease. Retrobulbar ON is the rule, not the exception.
Two thirds of acute ON presentations have a normal-appearing optic disc because the inflammation is posterior (retrobulbar) and does not produce disc edema visible ophthalmoscopically. A patient with acute monocular visual loss, pain on eye movement, RAPD, and dyschromatopsia has ON regardless of disc appearance. The disc swelling of papillitis (the other third) is not required for the diagnosis. OCT-RNFL will show peripapillary edema acutely even with a clinically normal disc , this can be helpful diagnostically and for baseline documentation before the post-inflammatory thinning develops.
MOG-IgG antibody disease is not MS and should not be treated as such.
MOG-antibody-associated disease (MOGAD) presents with ON , often bilateral, often with disc swelling, and often with better visual recovery than MS-related ON. It has a relapsing course but does not cause the chronic progressive neurological disability of MS. Crucially, interferon-beta and natalizumab used for MS may be ineffective or poorly tolerated in MOGAD, while azathioprine, mycophenolate, or rituximab are the preferred maintenance agents. The MOG-IgG blood test is increasingly available and should be checked in all bilateral or recurrent ON, particularly in cases with disc swelling and good recovery between episodes.

Further reading: AAO Neuro-Ophthalmology PPP. Related conditions: IIH (disc swelling differential), glaucoma (optic nerve differential). Subspecialty context: neuro-ophthalmology subspecialty page.